Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has spread to the liver, confirmed by a biopsy.
- Your cancer is MSS or pMMR type (a certain genetic feature).
- You have not had chemotherapy, radiation, or immunotherapy for this cancer before.
- Your overall health is good enough to carry out daily activities (Karnofsky score 70 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a short course of radiation followed by chemotherapy and targeted drugs for people with rectal cancer that has spread and cannot be removed with surgery. It aims to see if this combination can shrink tumors and improve outcomes.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a short course of radiation therapy combined with chemotherapy and immunotherapy for people with mid-to-low rectal cancer that hasn't spread. It aims to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Rectal Cancer With Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.